yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Computing
Conference & Expo
November 2-4, 2009 NYC
Register Today and SAVE !..

2008 West
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
Red Hat
The Opening of Virtualization
User Environment Management – The Third Layer of the Desktop
Cloud Computing for Business Agility
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Return on Assests: Bringing Visibility to your SOA Strategy
Managing Hybrid Endpoint Environments
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
How Can AJAX Improve Homeland Security?
Beyond Widgets: What a RIA Platform Should Offer
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
In many cases, the end of the year gives you time to step back and take stock of the last 12 months. This is when many of us take a hard look at what worked and what did not, complete performance reviews, and formulate plans for the coming year. For me, it is all of those things plus a time when I u...
Cadence Pharmaceuticals Reports Third Quarter 2012 Financial Results

SAN DIEGO, Nov. 5, 2012  /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the third quarter and nine months ended September 30, 2012.

Highlights from the third quarter include:

  • Net product revenue for the third quarter of 2012 was $13.9 million, an increase of $2.8 million, or 25%, from $11.1 million for the second quarter of 2012
  • Net product revenue for the nine months ended September 30, 2012, was $33.0 million, which is $27.4 million, or nearly five times, higher than the $5.6 million of net product revenue reported for the same period in 2011
  • The customer base for OFIRMEV increased by 10% during the third quarter as compared to the second quarter of this year, with a total of nearly 3,500 unique customer accounts at September 30, 2012
  • The gross margin on sales of OFIRMEV was 56% for the third quarter of 2012, which represents an improvement over the 48% gross margin reported for the second quarter of 2012
  • As of September 30, 2012, OFIRMEV was on formulary at over 2,000 institutions throughout the U.S.

"With strong third quarter sales growth and continued expansion of its user base, we believe that OFIRMEV, used as the foundation of a multimodal analgesic approach, is on track to become a standard of care in acute pain management. An increasing number of physicians and hospitals are choosing OFIRMEV to effectively manage acute pain and to reduce opioid use. OFIRMEV's customer base has nearly doubled over the past year and it is now being used in over 70% of the top 2,000 accounts in the country, when ranked by the quantity of IV analgesic products purchased," said Ted Schroeder, President and CEO of Cadence.

Financial Results

For the three months ended September 30, 2012, Cadence reported net product revenue of $13.9 million, an increase of $10.4 million from the $3.5 million of net product revenue reported for the three months ended September 30, 2011. For the nine months ended September 30, 2012, the company reported net product revenue of $33.0 million, an increase of $27.4 million from the $5.6 million of net product revenue reported for the corresponding period in 2011. During the nine months ended September 30, 2012, the company reported less than $0.1 million in licensing revenue, as compared to $5.2 million reported for the nine month period ended September 30, 2011, which was primarily related to a one-time data license to Terumo Corporation, which intends to seek regulatory approval in Japan for the same intravenous formulation of acetaminophen as OFIRMEV. No licensing revenue was reported for the three months ended September 30, 2011, or 2012.

For the three months ended September 30, 2012, Cadence reported a net loss of $15.9 million, or $0.19 per share, compared to a net loss of $21.8 million, or $0.34 per share, for the comparable period in 2011. For the nine months ended September 30, 2012, the company's net loss was $59.6 million, or $0.70 per share, compared to a net loss of $65.4 million, or $1.03 per share, for the comparable period in 2011.

Cost of product sales for the three months ended September 30, 2012, was approximately 44% of net product revenue, compared to 65% for the comparable period in 2011. The reduction in costs was mostly attributable to increased efficiencies from higher production volumes in 2012, while net product revenue benefitted from a higher net selling price as a result of a price increase implemented in July 2012. In addition, the company's cost of product sales for the three months ended September 30, 2011, was negatively impacted by an accrual for minimum royalty obligations. For the nine months ended September 30, 2012, cost of product sales was 49% of net product revenue, compared to 64% for the comparable period in 2011. This decrease includes efficiencies achieved in 2012 as a result of higher production volumes, which were partially offset by higher freight costs resulting from the company's temporary supply disruption during the first quarter of this year, unabsorbed manufacturing costs, and an inventory write-down. These excess costs were primarily related to Cadence's previously reported suspension of production of OFIRMEV at its initial contract manufacturer's facility.

Research and development expenses for the three months ended September 30, 2012, increased $0.5 million to $2.2 million, from $1.7 million for the comparable period in 2011. This increase was primarily a result of severance obligations related to the departure of two of the company's officers, and included approximately $0.3 million of non-cash, stock-based compensation expense. For the nine months ended September 30, 2012, the company reported research and development expenses of $5.4 million, a decrease of $1.6 million from the $7.0 million reported for the comparable period in 2011. This reduction was primarily attributable to the workforce restructuring implemented in the fourth quarter of 2011, partially offset by severance charges incurred during the third quarter of 2012.

Selling, general and administrative costs for the three months ended September 30, 2012, increased $0.1 million to $20.0 million, from $19.9 million for the three months ended September 30, 2011. For the nine months ended September 30, 2012, selling, general and administrative expenses increased $5.8 million to $66.8 million, from $61.0 million for the comparable period in 2011. This increase was mostly attributable to legal costs incurred in relation to the company's ongoing intellectual property litigation, and increased commissions earned by Cadence's hospital sales specialists due to increased product sales.  

As of September 30, 2012, Cadence reported cash, cash equivalents and short-term investments of $74.5 million and net accounts receivable of $6.8 million.


As of November 5, 2012, Cadence expects that net product revenue from sales of OFIRMEV for the three months ending December 31, 2012, will range from approximately $15.9 million to $16.4 million.

Conference Call and Webcast on November 5, 2012 at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time)

Cadence management will host a conference call on November 5, 2012, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) and interested investors may participate in the conference call by dialing (877) 303-9145 (domestic) or (760) 536-5203 (international). To access the webcast, please visit the company's website at and go to the Investors page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call. Cadence uses the Investors portion of its website as one means of disclosing material non-public information, and investors are encouraged to monitor Cadence's website in addition to following the company's press releases, SEC filings and public conference calls and webcasts.

About OFIRMEV® (Acetaminophen) Injection

OFIRMEV (acetaminophen) injection (1000 mg / 100 mL, 10 mg / mL; for intravenous use only), Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The FDA approval of OFIRMEV was based on data from clinical trials in approximately 1,020 adult and 355 pediatric patients. These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain, and one study evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.

Important Safety Information

Do not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. OFIRMEV should be administered only as a 15-minute intravenous infusion. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.

For more information, please see the complete OFIRMEV Prescribing Information, available at or

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting. The current version of Cadence Pharmaceuticals' corporate overview may be viewed on the Investors page of under "Events & Presentations" by selecting "Corporate Overview."

Forward-Looking Statements

Statements included in this press release and Cadence's conference call that are not a description of historical facts are forward-looking statements. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Such statements include, without limitation, statements regarding: Cadence's belief that OFIRMEV is on track to become a standard of care in acute pain management; Cadence's expectation that an increasing number of physicians are choosing OFIRMEV to effectively manage acute pain and reduce opioid use; and the company's guidance regarding net product revenue from sales of OFIRMEV for the fourth quarter of 2012. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Cadence's actual future results may differ materially from Cadence's current expectations due to the risks and uncertainties inherent in its business. These risks include, but are not limited to: Cadence's dependence on the successful commercialization of OFIRMEV, which is the company's only product; Cadence's ability to achieve broad market acceptance and generate revenues from sales of OFIRMEV; Cadence's dependence on its contract manufacturers and its ability to ensure an adequate and continued supply of OFIRMEV to meet market demand; Cadence's ability to successfully enforce its marketing exclusivities and intellectual property rights, and to defend the patents covering OFIRMEV, including in current patent litigation with the parties that have submitted abbreviated new drug applications ("ANDAs") for generic versions of OFIRMEV; the potential that Cadence may be required to continue patent litigation for substantial lengths of time or file additional lawsuits to defend its patent rights from challenges by companies that have submitted ANDAs for generic versions of OFIRMEV, and the substantial costs associated with such lawsuits; the potential introduction of generic competition to OFIRMEV in the event Cadence is unsuccessful in current or future patent litigation; Cadence's dependence on its licensors for the maintenance and enforcement of its intellectual property rights; the potential product liability exposure associated with pharmaceutical products such as OFIRMEV and other products Cadence may in-license or acquire; Cadence's ability to fully comply with numerous federal, state and local laws and regulatory requirements that apply to its commercial activities; public concern regarding the safety of drug products such as OFIRMEV, which could result in the implementation by regulatory agencies of new requirements to include unfavorable information in the labeling for OFIRMEV; the risk that Cadence may not be able to raise sufficient capital when needed, or at all; and other risks detailed under "Risk Factors" and elsewhere in Cadence's periodic reports and other filings made with the Securities and Exchange Commission from time to time. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995, and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Cadence® and OFIRMEV® are trademarks of Cadence Pharmaceuticals, Inc.


William R. LaRue

Kelli France

SVP & Chief Financial Officer

Media Relations

Cadence Pharmaceuticals, Inc.


Phone: 858-436-1400

Phone:  415-946-1076


(in thousands, except per share amounts)

Three Months Ended

Nine Months Ended

September 30,

September 30,






Product revenue, net

$       13,898

$        3,541

$       32,977

$        5,597

License revenues





            Total revenues





Costs and expenses:

Cost of product sales





Amortization of patent license





Research and development





Selling, general and administrative










            Total costs and expenses





Loss from operations





Other expense, net





Net loss

$     (15,890)

$     (21,829)

$     (59,552)

$     (65,415)

Basic and diluted net loss per share(1)

$        (0.19)

$        (0.34)

$        (0.70)

$        (1.03)

Shares used to compute basic and diluted net loss per share(1)





(1)  There is a lack of comparability in the per share amounts between the periods presented as a result of the issuance of 21,800 shares of common stock pursuant to a public offering in November 2011


(in thousands)

September 30,

December 31,





Current assets:

    Cash, cash equivalents and short-term investments 

$            74,529

$          127,227

    Restricted cash 



    Accounts receivable, net 






    Prepaid expenses and other current assets 



        Total current assets



Property and equipment, net



Intangible assets, net



Restricted cash



Other assets



        Total assets

$          117,082

$          164,160

Liabilities and Stockholders' Equity 

Current liabilities:

    Accounts payable 

$             6,313

$             3,801

    Accrued liabilities 



    Deferred revenue 



    Current debt, less discount 



        Total current liabilities



Other liabilities



Long-term debt, less discount



Total stockholders' equity



        Total liabilities and stockholders' equity

$          117,082

$          164,160

SOURCE Cadence Pharmaceuticals, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

SOA World Latest Stories
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York and Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Int...
Just over a week ago I received a long and loud sustained applause for a presentation I delivered at this year’s Cloud Expo in Santa Clara. I was extremely pleased with the turnout and had some very good conversations with many of the attendees. Over the next few days I had many more m...
DevOps is about increasing efficiency, but nothing is more inefficient than building the same application twice. However, this is a routine occurrence with enterprise applications that need both a rich desktop web interface and strong mobile support. With recent technological advances ...
As organizations realize the scope of the Internet of Things, gaining key insights from Big Data, through the use of advanced analytics, becomes crucial. However, IoT also creates the need for petabyte scale storage of data from millions of devices. A new type of Storage is required wh...
Culture is the most important ingredient of DevOps. The challenge for most organizations is defining and communicating a vision of beneficial DevOps culture for their organizations, and then facilitating the changes needed to achieve that. Often this comes down to an ability to provide...
Microservices are a very exciting architectural approach that many organizations are looking to as a way to accelerate innovation. Microservices promise to allow teams to move away from monolithic "ball of mud" systems, but the reality is that, in the vast majority of organizations, di...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)!

Advertise on this site! Contact advertising(at)! 201 802-3021

SYS-CON Featured Whitepapers